Amicus Therapeutics (FOLD) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

FOLD Amicus Therapeutics

Watchlist

9.660
+0.160+1.68%

Close Nov 22 16:00 ET

9.880
+0.220+2.28%

Post 18:53 ET

2.89BMarket Cap-28411P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

BioNJ Unveils "Time Off for Clinical Trials" Initiative
PR NewswireNov 20 10:00 ET
HALO Vs. FOLD: Which Stock Should Value Investors Buy Now?
Zacks Nov 19 10:50 ET
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
Seeking AlphaNov 17 09:18 ET
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
BenzingaNov 12 15:02 ET
J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Announces Target Price $17
Moomoo NewsNov 12 12:32 ET · Ratings
Amicus Therapeutics Price Target Raised to $17.00/Share From $16.00 by JP Morgan
Dow JonesNov 12 10:23 ET · Ratings

Comments

Meltyy

May 16 01:29

🔔 Perceptive Advisors Q1 ‘24* Holdings Released... 🐳

» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
...

Moomoo AI

Feb 7 06:42

Despite Amicus Therapeutics' recent share price uptick and steady revenue growth, the market's high expectations are reflected in the share price fall over the past three years. The company's 3.2% total shareholder return over the last twelve months falls short of the market return.

Strong Week for Amicus Therapeutics (NASDAQ:FOLD) Shareholders Doesn't Alleviate Pain of Three-year Loss

Moomoo AI

Jan 3 05:28

Investors might overlook Amicus Therapeutics' below industry-level growth forecast, risking future disappointment if the P/S ratio falls in line with the growth outlook. Moderate P/S ratio poses a risk as weaker revenue outlook might lead to share price drop.